コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 ty-based lymphomas (BCBL), and some forms of Castleman's disease.
2 imary effusion lymphoma, and a proportion of Castleman's disease.
3 odgkin's lymphomas (NHL) and in multicentric Castleman's disease.
4 an's disease from 1923 cases of multicentric Castleman's disease.
5 y-based lymphomas (BCBL) and in multicentric Castleman's disease.
6 sed lymphomas, and AIDS-related multicentric Castleman's disease.
7 , and from a high proportion of multicentric Castleman's disease.
8 primary effusion lymphoma, and multicentric Castleman's disease.
9 for, and outcomes of idiopathic multicentric Castleman's disease.
10 uch cases are called idiopathic multicentric Castleman's disease.
11 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
12 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
13 6-in HIV-negative patients with multicentric Castleman's disease.
14 ative patients with symptomatic multicentric Castleman's disease.
15 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
16 or at least 33% of all cases of multicentric Castleman's disease.
17 primary effusion lymphoma, and multicentric Castleman's disease.
18 g primary effusion lymphoma and multicentric Castleman's disease.
19 ary effusion lymphoma (PEL) and multicentric Castleman's disease.
20 primary effusion lymphoma, and multicentric Castleman's disease.
21 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
22 f primary effusion lymphoma and multicentric Castleman's disease.
23 g primary effusion lymphoma and multicentric Castleman's disease.
24 primary effusion lymphomas, and multicentric Castleman's disease.
25 primary effusion lymphoma, and multicentric Castleman's disease.
26 ion lymphoma, and some forms of multicentric Castleman's disease.
27 primary effusion lymphoma, and multicentric Castleman's disease.
28 primary effusion lymphoma, and multicentric Castleman's disease.
29 primary effusion lymphoma, and multicentric Castleman's disease.
30 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
31 ion lymphoma, and plasmablastic multicentric Castleman's disease.
32 primary effusion lymphoma, and multicentric Castleman's disease.
33 primary effusion lymphoma, and multicentric Castleman's disease.
34 ondylitis, familial Mediterranean fever, and Castleman's disease.
35 f primary effusion lymphoma and multicentric Castleman's disease.
36 primary effusion lymphoma, and multicentric Castleman's disease.
37 a and the plasmablastic form of multicentric Castleman's disease.
38 n lymphoma and in some cases of multicentric Castleman's disease.
39 thritis, hypercalcemia, cancer cachexia, and Castleman's disease.
40 primary effusion lymphoma, and multicentric Castleman's disease.
41 n primary effusion lymphoma and multicentric Castleman's disease.
42 , primary effusion lymphoma and multicentric Castleman's disease.
43 primary effusion lymphoma, and multicentric Castleman's disease.
44 i's sarcoma, body cavity-based lymphoma, and Castleman's disease.
45 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
46 primary effusion lymphoma, and multicentric Castleman's disease.
47 primary effusion lymphoma, and multicentric Castleman's disease.
48 primary effusion lymphoma, and multicentric Castleman's disease.
49 dy cavity-based lymphomas, and some forms of Castleman's disease.
50 primary effusion lymphoma, and multicentric Castleman's disease.
51 si's sarcoma, primary effusion lymphoma, and Castleman's disease.
52 ry effusion lymphoma (PEL), and multicentric Castleman's disease.
53 sion lymphoma and some cases of multicentric Castleman's disease.
56 ma-herpesvirus that causes Kaposi's sarcoma, Castleman's disease and primary effusion lymphomas in tr
57 e for patients with symptomatic multicentric Castleman's disease and well tolerated with prolonged ex
58 from January, 1995, with keywords including "Castleman's disease" and "giant lymph node hyperplasia".
59 ogic agent of Kaposi's sarcoma, multicentric Castleman's disease, and AIDS-associated primary effusio
60 ) are associated with Kaposi's sarcoma (KS), Castleman's disease, and body cavity-based lymphomas (BC
62 V-8) and its etiologic associations with KS, Castleman's disease, and primary effusion lymphomas.
64 found in Kaposi's sarcoma (KS), multicentric Castleman's disease, and primary effusion lymphomas.
65 si's sarcoma, primary effusion lymphoma, and Castleman's disease are the major malignancies associate
66 lopment of Kaposi's sarcoma and multicentric Castleman's disease, as well as a rare form of B cell ly
67 h primary effusion lymphoma and multicentric Castleman's disease, as well as its namesake Kaposi's sa
68 plasia to monoclonal neoplasia: multicentric Castleman's disease (CD), Kaposi's sarcoma (KS), and pri
71 ling the multicentric plasma cell variant of Castleman's disease, characterized by persistent angiofo
74 si's sarcoma, primary effusion lymphoma, and Castleman's disease, encodes several pathogenically impo
75 3%) patients with HHV8-negative multicentric Castleman's disease from 1923 cases of multicentric Cast
77 of 128 patients with idiopathic multicentric Castleman's disease had a diagnosis of a separate malign
79 Inclusion criteria were pathology-confirmed Castleman's disease in multiple nodes and minimum clinic
80 primary effusion lymphoma, and multicentric Castleman's disease; in all of these diseases, interleuk
81 -line treatments for idiopathic multicentric Castleman's disease included corticosteroids (47/128 [37
82 Clinical features of idiopathic multicentric Castleman's disease included multicentric lymphadenopath
87 ted in KSHV-positive cells from multicentric Castleman's disease (MCD) and Kaposi's sarcoma (KS) lesi
89 phoma (PEL) cell lines, PEL and multicentric Castleman's disease (MCD) tumors, Kaposi's sarcoma lesio
90 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), all of which are viewed as cy
91 inked to Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma
92 ncluding Kaposi's sarcoma (KS), multicentric Castleman's disease (MCD), and primary effusion lymphoma
93 rimary effusion lymphoma (PEL), multicentric Castleman's disease (MCD), and the inflammation-driven n
94 (UCD) or the dominant focus in multicentric Castleman's disease (MCD), nature of the surgical approa
95 ry effusion lymphoma (PEL), and multicentric Castleman's disease (MCD), three diseases that frequentl
105 128 patients with idiopathic multicentric Castleman's disease met all inclusion criteria for the s
106 tic pemphigus (including 10 with concomitant Castleman's disease) nor from 19 patients with pemphigus
107 ed information about idiopathic multicentric Castleman's disease represents a major challenge for cli
108 ted with human herpesvirus-8 in multicentric Castleman's disease support lytic replication, so that c
109 ated with both malignancies and multicentric Castleman's disease; the latter is a rare angiolymphopro
110 less commonly primary effusion lymphoma and Castleman's disease; these neoplastic diseases are repor
111 ry effusion lymphoma (PEL), and multicentric Castleman's disease through autocrine or paracrine mecha
112 K1 was readily detected in multicentric Castleman's disease tissues, whereas it was not detected
113 systematic review of 404 published cases of Castleman's disease to identify the role of the surgeon
114 cal location of the only focus in unicentric Castleman's disease (UCD) or the dominant focus in multi
115 or 127 patients with idiopathic multicentric Castleman's disease were presented from clinical trials,
116 ent, and outcomes of idiopathic multicentric Castleman's disease, which accounts for at least 33% of
117 there is mild FDG localization within pelvic Castleman's disease with standard uptake values lower th
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。